

ADVANCE VOTING FORM

Faron Pharmaceuticals Ltd Annual General Meeting on 23 April 2021 at 2:00 p.m. (EEST)

With this form, I/we authorize Innovatics Oy (“Innovatics”), the advance voting service provider for Faron Pharmaceuticals Ltd’s Annual General Meeting 2021, to register my/our votes with the shares I/we own/represent in certain items of the agenda of the Annual General Meeting 2021 of Faron Pharmaceuticals Ltd.

I/we understand that voting in advance by submitting this form requires that the shareholder has at least one valid Finnish book-entry account. The number of advance votes is confirmed on the Finnish record date of the Annual General Meeting (13 April 2021) based on the holding in the book-entry account.

Shareholder’s name	
Finnish personal ID-code or business ID (Y-tunnus)	
Phone number	

Please note that you may vote in advance also electronically at the address <https://www.faron.com/investors/general-meetings>.

Voting instructions:

I/we authorize Innovatics Oy to register my/our votes with the shares I/we own/represent in each of the items of the agenda of the meeting as indicated with a cross (X) below.

If no voting instructions have been indicated below, or if there are more than one voting instructions on the same item, or if other text or markings other than a cross (X) have been used to indicate a voting instruction, this means that the shareholder's shares are not taken into consideration in the item in question. The shareholder's shares are not considered as shares represented at the meeting and the votes are not counted as cast votes with regard to the item in question.

I/we understand that if I/we give advance votes as a representative of an entity (incl. estate), the legal representative of the entity or a person authorized by the entity must provide necessary documents to prove the right to represent the entity (e.g. trade register extract or board resolution). Documents are requested to be attached to this advance voting form. If the documents are not submitted during the advance voting period or they are otherwise incomplete, the shares of the entity will not be included as shares represented at the Annual General Meeting.

It is recommended that a Finnish book-entry account holder votes in advance electronically at the address <https://www.faron.com/investors/general-meetings>. In a situation where the Finnish book-entry account holder has voted in advance both electronically and via this advance voting form, Innovatics will register the most recent voting instruction.

[Continues on the next page]

Matters to be resolved on at the Annual General Meeting 2021 of Faron Pharmaceuticals Ltd:

Agenda items 7 to 17 cover proposals of the Board of Directors of Faron Pharmaceuticals Oy to the Annual General Meeting in accordance with the notice of the meeting. “**Abstain from voting**” means giving an empty vote, in which case the shares are taken into account as shares represented in the handling of the agenda item, which has an impact with respect to resolutions requiring a qualified majority (e.g. agenda items 15 to 17). With respect to resolutions requiring a qualified majority, all shares represented at the Annual General Meeting are taken into account. Therefore, abstaining from voting has an impact on the outcome of the vote. Shareholders should be aware of this fact, especially if their intention is not to vote against the proposal.

	Resolution item	For/Yes	Against/No	Abstain from voting
7.	Adoption of the financial statements	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
8.	Resolution on the use of the profit shown on the balance sheet and the payment of dividend	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
9.	Resolution on the discharge of the members of the Board and the CEO of the Company from liability	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
10.	Resolution on the remuneration of the members of the Board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
11.	Resolution on the number of members of the Board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
12.	Election of members of the Board	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
13.	Resolution on the remuneration of the auditor	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
14.	Election of the auditor	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
15.	Resolution on the amendment of the Option Plan 2015	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
16.	Amendment of the Articles of Association	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
17.	Authorising the Board to decide on the issuance of shares, options or other special rights entitling to shares	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

Place and date	
Signature	
Name in capital letters	

To be returned in a completed and signed form either by email to agm@innovatics.fi or by letter to Innovatics Ltd, Yhtiökokous / Faron Pharmaceuticals Ltd, Ratamestarinkatu 13 A, FI-00520 Helsinki, Finland. **The delivery must be received by 19 April 2021 at 10:00 a.m. (EEST) at the latest.**